860787-38-8

Basic information

• Product Name: 3-[(TERT-BUTOXYCARBONYL)AMINO]-3-(2,4-DIFLUOROPHENYL)PROPANOIC ACID
• Synonyms: 3-[(TERT-BUTOXYCARBONYL)AMINO]-3-(2,4-DIFLUOROPHENYL)PROPANOIC ACID
• CAS NO: 860787-38-8
• Molecular Formula: C14H17F2NO4
• Molecular Weight: 301.29
• Mol File: 860787-38-8.mol

Chemical Properties

• Boiling Point: 415.3±45.0 °C(Predicted)
• Appearance: /
• Density: 1.268±0.06 g/cm3(Predicted)
• PKA: 4.30±0.10(Predicted)
• CAS DataBase Reference: 3-[(TERT-BUTOXYCARBONYL)AMINO]-3-(2,4-DIFLUOROPHENYL)PROPANOIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 3-[(TERT-BUTOXYCARBONYL)AMINO]-3-(2,4-DIFLUOROPHENYL)PROPANOIC ACID(860787-38-8)
• EPA Substance Registry System: 3-[(TERT-BUTOXYCARBONYL)AMINO]-3-(2,4-DIFLUOROPHENYL)PROPANOIC ACID(860787-38-8)

Safety Data

• Hazardous Substances Data: 860787-38-8(Hazardous Substances Data)

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 412925-23-6 rac-3-amino-3-(2,4-difluorophenyl)propanoic acid 

Relevant articles and documents

1-PHENYLPYRROLIDIN-2-ONE DERIVATIVES AS PERK INHIBITORS

The invention is directed to substituted pyrrolidinone and imidazolidinone derivatives. Specifically, the invention is directed to compounds according to Formula I: (I) wherein R1, R2, R3, R4, R5, R6, R7, X and Y are as defined herein. The compounds of the invention are inhibitors of PERK and can be useful in the treatment of cancer, pre-cancerous syndromes and diseases/injuries associated with activated unfolded protein response pathways, such as Alzheimer's disease, neuropathic pain, spinal cord injury, traumatic brain injury, ischemic stroke, stroke, Parkinson's disease, diabetes, metabolic syndrome, metabolic disorders, Huntington's disease, Creutzfeldt- Jakob Disease, fatal familial insomnia, Gerstmann-Str?ussler-Scheinker syndrome, and related prion diseases, amyotrophic lateral sclerosis, progressive supranuclear palsy, myocardial infarction, cardiovascular disease, inflammation, organ fibrosis, chronic and acute diseases of the liver, fatty liver disease, liver steatosis, liver fibrosis, chronic and acute diseases of the lung, lung fibrosis, chronic and acute diseases of the kidney, kidney fibrosis, chronic traumatic encephalopathy (CTE), neurodegeneration, dementias, frontotemporal dementias, tauopathies, Pick's disease, Neimann-Pick's disease, amyloidosis, cognitive impairment, atherosclerosis, ocular diseases, arrhythmias, in organ transplantation and in the transportation of organs for transplantation. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting PERK activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

COMPLEMENT PATHWAY MODULATORS AND USES THEREOF

The present invention provides a compound of formula I a method for manufacturing the compounds of the invention, and its therapeutic uses as inhibitor of the complement alternative pathway and particularly as inhibitor of Factor B for the treatment of e.g. age-related macular degeneration and diabetic retinopathy. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.